These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

442 related articles for article (PubMed ID: 32504692)

  • 61. Novel drugs for the treatment of chronic pruritus.
    Pereira MP; Ständer S
    Expert Opin Investig Drugs; 2018 Dec; 27(12):981-988. PubMed ID: 30426802
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Topical κ-opioid receptor agonist asimadoline improves dermatitis in a canine model of atopic dermatitis.
    Marsella R; Ahrens K; Wilkes R; Soeberdt M; Abels C
    Exp Dermatol; 2022 Apr; 31(4):628-632. PubMed ID: 34839557
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Efficacy of a Moisturizing Foam in Skin Barrier Regeneration and Itch Relief in Subjects Prone to Atopic Dermatitis.
    Lio PA
    J Drugs Dermatol; 2016 Nov; 15(11):s77-s80. PubMed ID: 28095568
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Medical treatment of pruritus.
    Ständer S; Weisshaar E
    Expert Opin Emerg Drugs; 2012 Sep; 17(3):335-45. PubMed ID: 22870909
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Antipruritic Effect of Nalbuphine, a Kappa Opioid Receptor Agonist, in Mice: A Pan Antipruritic.
    Inan S; Dun NJ; Cowan A
    Molecules; 2021 Sep; 26(18):. PubMed ID: 34576988
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Phosphodiesterase 4 inhibitors.
    Zebda R; Paller AS
    J Am Acad Dermatol; 2018 Mar; 78(3 Suppl 1):S43-S52. PubMed ID: 29248522
    [TBL] [Abstract][Full Text] [Related]  

  • 67. A pharmacological profile of the novel, peripherally-selective kappa-opioid receptor agonist, EMD 61753.
    Barber A; Bartoszyk GD; Bender HM; Gottschlich R; Greiner HE; Harting J; Mauler F; Minck KO; Murray RD; Simon M
    Br J Pharmacol; 1994 Dec; 113(4):1317-27. PubMed ID: 7889287
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Spontaneous scratching behaviour in DS-Nh mice as a possible model for pruritus in atopic dermatitis.
    Yoshioka T; Hikita I; Asakawa M; Hirasawa T; Deguchi M; Matsutani T; Oku H; Horikawa T; Arimura A
    Immunology; 2006 Jul; 118(3):293-301. PubMed ID: 16827890
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Anti-Pruritic Efficacy of Itch Relief Lotion and Cream in Patients With Atopic History: Comparison With Hydrocortisone Cream.
    Zirwas MJ; Barkovic S
    J Drugs Dermatol; 2017 Mar; 16(3):243-247. PubMed ID: 28301620
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Pruritus in psoriasis and atopic dermatitis: current treatments and new perspectives.
    Kahremany S; Hofmann L; Harari M; Gruzman A; Cohen G
    Pharmacol Rep; 2021 Apr; 73(2):443-453. PubMed ID: 33460006
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Antipruritic activity of the kappa-opioid receptor agonist, TRK-820.
    Togashi Y; Umeuchi H; Okano K; Ando N; Yoshizawa Y; Honda T; Kawamura K; Endoh T; Utsumi J; Kamei J; Tanaka T; Nagase H
    Eur J Pharmacol; 2002 Jan; 435(2-3):259-64. PubMed ID: 11821035
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Recent studies of cutaneous nociception in atopic and non-atopic subjects.
    Heyer GR; Hornstein OP
    J Dermatol; 1999 Feb; 26(2):77-86. PubMed ID: 10091477
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Phase 1 studies to assess the safety, tolerability and pharmacokinetics of JTE-052 (a novel Janus kinase inhibitor) ointment in Japanese healthy volunteers and patients with atopic dermatitis.
    Nakagawa H; Nemoto O; Yamada H; Nagata T; Ninomiya N
    J Dermatol; 2018 Jun; 45(6):701-709. PubMed ID: 29665062
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Interleukin-31 and interleukin-31 receptor: New therapeutic targets for atopic dermatitis.
    Nakashima C; Otsuka A; Kabashima K
    Exp Dermatol; 2018 Apr; 27(4):327-331. PubMed ID: 29524262
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Novel therapies in the treatment of atopic dermatitis.
    Zhong CS; Elmariah SB
    Semin Cutan Med Surg; 2018 Sep; 37(3):190-197. PubMed ID: 30215637
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Therapeutic pipeline for atopic dermatitis: End of the drought?
    Paller AS; Kabashima K; Bieber T
    J Allergy Clin Immunol; 2017 Sep; 140(3):633-643. PubMed ID: 28887947
    [TBL] [Abstract][Full Text] [Related]  

  • 77. OPA-15406, a novel, topical, nonsteroidal, selective phosphodiesterase-4 (PDE4) inhibitor, in the treatment of adult and adolescent patients with mild to moderate atopic dermatitis (AD): A phase-II randomized, double-blind, placebo-controlled study.
    Hanifin JM; Ellis CN; Frieden IJ; Fölster-Holst R; Stein Gold LF; Secci A; Smith AJ; Zhao C; Kornyeyeva E; Eichenfield LF
    J Am Acad Dermatol; 2016 Aug; 75(2):297-305. PubMed ID: 27189825
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Substance P restores normal skin architecture and reduces epidermal infiltration of sensory nerve fiber in TNCB-induced atopic dermatitis-like lesions in NC/Nga mice.
    Choi H; Kim DJ; Nam S; Lim S; Hwang JS; Park KS; Hong HS; Won Y; Shin MK; Chung E; Son Y
    J Dermatol Sci; 2018 Mar; 89(3):248-257. PubMed ID: 29269174
    [TBL] [Abstract][Full Text] [Related]  

  • 79. [Pruritus in atopic dermatitis-comparative evaluation of novel treatment approaches].
    Müller S; Witte F; Ständer S
    Dermatologie (Heidelb); 2022 Jul; 73(7):538-549. PubMed ID: 35925206
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Innovation in the treatment of atopic dermatitis: Emerging topical and oral Janus kinase inhibitors.
    Nakashima C; Yanagihara S; Otsuka A
    Allergol Int; 2022 Jan; 71(1):40-46. PubMed ID: 34815171
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.